company background image
UQ1 logo

uniQure DB:UQ1 Stock Report

Last Price

€4.58

Market Cap

€233.7m

7D

8.4%

1Y

-74.8%

Updated

24 Mar, 2024

Data

Company Financials +

UQ1 Stock Overview

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases.

UQ1 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

uniQure N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for uniQure
Historical stock prices
Current Share PriceUS$4.58
52 Week HighUS$20.05
52 Week LowUS$4.23
Beta0.96
1 Month Change-18.21%
3 Month Change-16.58%
1 Year Change-74.85%
3 Year Change-81.57%
5 Year Change-91.11%
Change since IPO-64.16%

Recent News & Updates

Recent updates

Shareholder Returns

UQ1DE BiotechsDE Market
7D8.4%4.5%1.4%
1Y-74.8%34.1%7.5%

Return vs Industry: UQ1 underperformed the German Biotechs industry which returned 34.1% over the past year.

Return vs Market: UQ1 underperformed the German Market which returned 7.5% over the past year.

Price Volatility

Is UQ1's price volatile compared to industry and market?
UQ1 volatility
UQ1 Average Weekly Movement10.7%
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: UQ1's share price has been volatile over the past 3 months.

Volatility Over Time: UQ1's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1998480Matt Kapustahttps://www.uniqure.com

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer’s disease; and AMT-210 that is in preclinical trial to treat Parkinson’s disease.

uniQure N.V. Fundamentals Summary

How do uniQure's earnings and revenue compare to its market cap?
UQ1 fundamental statistics
Market cap€233.74m
Earnings (TTM)-€285.47m
Revenue (TTM)€14.66m

15.9x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
UQ1 income statement (TTM)
RevenueUS$15.84m
Cost of RevenueUS$212.60m
Gross Profit-US$196.75m
Other ExpensesUS$111.72m
Earnings-US$308.48m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-6.45
Gross Margin-1,241.90%
Net Profit Margin-1,947.09%
Debt/Equity Ratio238.8%

How did UQ1 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.